申请人:CTG Pharma S.r.l.
公开号:EP1645288A1
公开(公告)日:2006-04-12
The present invention relates to novel compounds that are nuclear transcription factors (NTF) regulators. The present invention also provides methods for treating, preventing and/or reducing inflammation-associated diseases by regulating NTF in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems as well as tumoral and infective diseases employing said compounds.
The present invention is based on the discovery that it is possible to link regulators of NTF to a pharmacologically active compound helpful for treating disorders in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems or tumoral and infective diseases. The resulting compounds have good bioavailability, increased activity and/or safety.
本发明涉及一种新型化合物,这些化合物是核转录因子(NTF)调节剂。本发明还提供了通过调节心血管、结缔组织、肺部、胃肠、呼吸、泌尿生殖、神经或皮肤系统以及肿瘤和感染性疾病中的NTF来治疗、预防和/或减少与炎症相关疾病的方法。本发明基于这样的发现:可以将NTF的调节剂与对治疗心血管、结缔组织、肺部、胃肠、呼吸、泌尿生殖、神经或皮肤系统或肿瘤和感染性疾病有帮助的药理活性化合物联系起来。由此产生的化合物具有良好的生物利用度、增强的活性和/或安全性。